Comparar compuestos
Seleccione hasta 3 compuestos para comparar protocolos, mecanismos, criterios de valoración y hallazgos de seguridad en paralelo.
Peptijournal · Cagrilintide vs Semaglutide · https://peptijournal.com/compare?c=cagrilintide,semaglutide · Impreso
01Protocol
Cagrilintide
- Viales
- 5 mg
- Datos de dosis
- Referencia de laboratorio; no indicado
Semaglutide
- Start
- 0.25 mg
- Range
- 0.25–2.4 mg
- Frequency
- Once weekly
- Cycle
- Ongoing, titrated every 4 weeks
- Vials
- 3 / 5 / 10 mg
- Ajuste gradual
- Weeks 1–4: 0.25 mg
- Weeks 5–8: 0.5 mg
- Weeks 9–12: 1.0 mg
- Weeks 13–16: 1.7 mg
- Weeks 17+: 2.4 mg
02Quick calculator
Cagrilintide
Semaglutide
03Mechanism of action
Cagrilintide
Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone that induces satiety. It is studied alone and combined with semaglutide (CagriSema).
Semaglutide
Semaglutide is a GLP-1 receptor agonist modified with a fatty-acid side chain that binds albumin, giving it a roughly week-long half-life. GLP-1 receptor activation increases glucose-dependent insulin secretion, lowers glucagon, slows gastric emptying and acts on brain appetite centres.
04Study endpoints
Cagrilintide
- Phase 2 (26 weeks): every cagrilintide arm reduced weight more than placebo (6.0%–10.8% vs 3.0%); the top arm also beat liraglutide (10.8% vs 9.0%).
- Combination evidence, not cagrilintide-alone efficacy: REDEFINE 1 (3,417 adults without diabetes) reported −20.4% mean weight change with cagrilintide–semaglutide vs −3.0% with placebo at 68 weeks using the treatment-policy estimand.
- Combination evidence in type 2 diabetes: REDEFINE 2 reported −13.7% mean weight change with cagrilintide–semaglutide vs −3.4% with placebo at 68 weeks, not a standalone cagrilintide result.
Semaglutide
- STEP 1 (adults with obesity, no diabetes): mean body-weight change of −14.9% vs −2.4% with placebo at week 68.
- SUSTAIN-6 (type 2 diabetes): major cardiovascular events in 6.6% vs 8.9% with placebo (hazard ratio 0.74).
- SELECT (cardiovascular disease + overweight, no diabetes): primary cardiovascular events in 6.5% vs 8.0% (hazard ratio 0.80).
05Safety & regulatory findings
Cagrilintide
- Investigational: not approved as a standalone medicine.
- Phase 2: gastrointestinal events in 41%–63% vs 32% on placebo, mainly nausea. REDEFINE 1 combination arm: gastrointestinal events in 79.6% vs 39.9% with placebo.
Semaglutide
- FDA-approved (as Ozempic, Wegovy and Rybelsus) for specific indications; research-grade material is not an approved product.
- Gastrointestinal effects were the most common adverse events; in SELECT, 16.6% stopped treatment for adverse events vs 8.2% on placebo.
- SUSTAIN-6 reported more diabetic retinopathy complications in the semaglutide group.